RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer

Authors: Marina Ciscar, Eva M Trinidad, Gema Perez‐Chacon, Mansour Alsaleem, Maria Jimenez, Maria J Jimenez‐Santos, Hector Perez‐Montoyo, Adrian Sanz‐Moreno, Andrea Vethencourt, Michael Toss, Anna Petit, Maria T Soler‐Monso, Victor Lopez, Jorge Gomez‐Miragaya, Clara Gomez‐Aleza, Lacey E Dobrolecki, Michael T Lewis, Alejandra Bruna, Silvana Mouron, Miguel Quintela‐Fandino, Fatima Al‐Shahrour, Antonio Martinez‐Aranda, Angels Sierra, Andrew R Green, Emad Rakha, Eva Gonzalez‐Suarez

Source: EMBO Molecular Medicine, Vol 15, Iss 4, Pp 1-12 (2023)

Subject Terms: breast cancer patient‐derived xenografts, ER negative breast cancer, menopause, pharmacological RANKL inhibitors, RANK‐RANKL, Medicine (General), R5-920, Genetics, QH426-470

File Description: electronic resource

Relation: https://doaj.org/toc/1757-4676; https://doaj.org/toc/1757-4684

Access URL: https://doaj.org/article/1a7e932a6a184ce6a384d4a58e43a0be

Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells

Authors: Clara Gómez-Aleza, Bastien Nguyen, Guillermo Yoldi, Marina Ciscar, Alexandra Barranco, Enrique Hernández-Jiménez, Marion Maetens, Roberto Salgado, Maria Zafeiroglou, Pasquale Pellegrini, David Venet, Soizic Garaud, Eva M. Trinidad, Sandra Benítez, Peter Vuylsteke, Laura Polastro, Hans Wildiers, Philippe Simon, Geoffrey Lindeman, Denis Larsimont, Gert Van den Eynden, Chloé Velghe, Françoise Rothé, Karen Willard-Gallo, Stefan Michiels, Purificación Muñoz, Thierry Walzer, Lourdes Planelles, Josef Penninger, Hatem A. Azim, Sherene Loi, Martine Piccart, Christos Sotiriou, Eva González-Suárez

Source: Nature Communications, Vol 11, Iss 1, Pp 1-18 (2020)

Subject Terms: Science

File Description: electronic resource

Relation: https://doaj.org/toc/2041-1723

Access URL: https://doaj.org/article/25343e5b801f4662be448798ebe81a76